Improved synthetic methods of CP-060S,a novel cardioprotective drug |
| |
| Institution: | 1. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA;2. Institute for Liver and Digestive Health, University College London, London, UK;3. Department of Engineering Sciences, Dartmouth College, Hanover, New Hampshire, USA;4. Department of Dermatology, Cleveland Clinic, Cleveland, Ohio, USA;5. Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, USA;1. Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani Campus, Pilani, Rajasthan, India;2. Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India;3. University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India;4. R&D Healthcare Division, Emami Ltd, Kolkata, West Bengal, India;1. Pharmacology Unit, Faculty of Pharmacy, Asian Institute of Medicine, Science and Technology (AIMST) University, Semeling, 08100 Bedong, Kedah Darul Aman, Malaysia;2. Pharmaceutical Technology Unit, Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman, Malaysia;1. School of Chemistry, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse Street, Dublin 2, Ireland;2. Irish Centre of High-End Computing, Grand Canal Quay, Dublin 2, Ireland;3. Department of Pharmacology, University of the Basque Country UPV/EHU, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain |
| |
| Abstract: | Two synthetic methods of CP-060S, (−)-2-(3,5-di-tert-butyl-4-hydroxyphenyl)-3-3-N-methyl-N-2-3,4-(methylenedioxy)phenoxy]ethyl]amino]propyl]-1,3-thiazolidin-4-one (−)-1, have been developed. The first method involved preparative HPLC resolution of bromo-intermediate 4. The second one involved resolution of 1 by crystallization of the corresponding diastereomeric salt. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
